RNTX Rein Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1420565 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY15.6%
TTM EPS YoY48.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-100.5%
ROA-87.9%
ROIC (approx.)-85.7%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets11.2%
Debt / equity0.00x
Current ratio6.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.45x
Accruals ratio-48.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $4.38M | $3.64M | $3.07M | $2.00M | $1.68M | $4.29M | $3.05M | $3.32M |
| SG&A expense | $2.62M | $2.44M | $2.16M | $1.96M | $3.81M | $2.58M | $2.56M | $2.48M |
| Operating income | -$7.00M | -$6.08M | -$5.23M | -$32.66M | -$5.49M | -$6.87M | -$5.61M | -$42.80M |
| Net income | -$5.54M | -$6.38M | -$5.84M | -$31.97M | -$5.58M | -$6.82M | -$5.50M | -$40.98M |
| EBITDA | -$7.00M | — | — | -$32.66M | -$5.49M | -$6.87M | -$5.61M | -$42.80M |
| EPS (basic) | -0.06 | -0.10 | -0.19 | — | -0.21 | -0.28 | -0.25 | — |
| EPS (diluted) | -0.06 | -0.10 | -0.19 | — | -0.21 | -0.28 | -0.25 | — |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 88.33M | 67.08M | 30.35M | — | 26.36M | 24.19M | 21.92M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $943,000 | $8.54M | $4.45M | $3.21M | $4.05M | $5.72M | $7.43M | $12.87M |
| Short-term investments | $34.55M | $32.10M | — | $0 | — | — | — | — |
| Current assets | $36.78M | $41.45M | $5.45M | $4.33M | $5.17M | $6.60M | $8.33M | $13.66M |
| PP&E, net | — | — | — | $0 | $0 | $1,000 | $1,000 | $1,000 |
| Goodwill | $6.33M | $6.33M | $6.33M | $6.33M | $6.33M | $6.33M | $6.33M | $6.33M |
| Intangibles | $13.50M | $13.50M | $13.50M | $13.50M | $42.20M | $42.20M | $42.20M | $42.20M |
| Total assets | $59.43M | $65.97M | $26.29M | $24.16M | $53.71M | $57.48M | $57.63M | $62.19M |
| Current liabilities | $5.60M | $9.71M | $13.64M | $6.18M | $5.74M | $7.69M | $5.98M | $5.75M |
| Total liabilities | $6.66M | $10.77M | $14.70M | $7.24M | $7.52M | $9.47M | $7.75M | $7.80M |
| Shareholders' equity | $52.77M | $55.20M | $11.59M | $16.92M | $46.19M | $48.01M | $49.88M | $54.39M |
| Shares outstanding | 86.27M | 85.77M | 28.04M | 27.55M | 25.14M | 23.05M | 22.01M | 21.67M |
| Cash flow statement | ||||||||
| Operating cash flow | -$7.27M | -$8.64M | -$3.42M | -$3.22M | -$3.55M | -$6.42M | -$6.17M | -$4.81M |
| Investing cash flow | -$329,000 | — | — | — | $0 | — | — | $0 |
| Financing cash flow | $0 | $47.81M | $4.65M | $2.40M | $1.90M | $4.71M | $738,000 | $1,000 |
| Depreciation & amortization | $0 | — | — | $0 | $0 | $1,000 | $0 | $0 |
| Stock-based compensation | $534,000 | $164,000 | $156,000 | $257,000 | $1.45M | $256,000 | $264,000 | $133,000 |
Free plan shows the latest 8 periods; Pro shows all 43 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.